“If I’m not dying, I better go live.” Christy Erickson’s cancer diagnosis led to life as a motorcyclist and strongman competitor

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Christy Erickson was seven years old when her mom lost a three-year battle with breast cancer. 

This is the fourth story in a series that marks the 20th anniversary of the publication of papers on the role of EGFR mutation in lung cancer. This multimedia series is guest-edited by Suresh S. Ramalingam, a lung cancer expert, executive director of Winship Cancer Institute of Emory University, and editor-in-chief of the journal Cancer. The series explores the process of discovery of EGFR mutations in lung cancer, the learning curve for using the drugs that target those mutations, and the unparalleled impact on patients with lung cancer and other diseases.

“Most of my memories of her are of her being in some form of treatment,” said Erickson, who is currently a stay-at-home mom of two teenagers in Macon, Georgia. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
McKenzie Prillaman
McKenzie Prillaman
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Nuvalent, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in tyrosine kinase inhibitor pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 phase I/II clinical trial. 
FDA has approved Hyrnuo (sevabertinib), an oral, reversible, tyrosine kinase inhibitor, for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
McKenzie Prillaman
McKenzie Prillaman
Reporter

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login